SCHEMBL2831985

SCHEMBL2831985

C=CCOC(=O)c1c(F)cc(F)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
TSHR P16473 2/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ERN1 O75460 1/20 0.39
KMT2A Q03164 3/20 0.39
SNCA P37840 1/20 0.39
GAA P10253 1/20 0.39
RHOA P61586 1/20 0.37
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
APP P05067 1/20 0.36
TP53 P04637 1/20 0.35
FGFR1 P11362 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2832548 0.84 CYP3A4 (0.47) CYP3A4TSHRPOLBMAPK1ALDH1A1
SCHEMBL2834467 0.83 KMT2A (0.37) CYP3A4TSHRPOLBMAPK1ALDH1A1
SCHEMBL2830668 0.82 CYP3A4 (0.58) CYP3A4TSHRPOLBALDH1A1HSD17B10
SCHEMBL2837871 0.81 KMT2A (0.41) TSHRPOLBERN1KMT2AGAA
SCHEMBL2837868 0.81 KMT2A (0.41) TSHRPOLBERN1KMT2AGAA
SCHEMBL2834534 0.80 ALDH1A1 (0.39) TSHRPOLBMAPK1ALDH1A1ERN1
SCHEMBL2838613 0.79 KMT2A (0.41) TSHRPOLBMAPK1KDM4EERN1
SCHEMBL2836042 0.79 MMP1 (0.43) TSHRALDH1A1KMT2AGAA
SCHEMBL28355427 0.79 CYP3A4 (0.52) CYP3A4TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL2831224 0.78 CYP3A4 (0.57) CYP3A4TSHRPOLBMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CYP3A4 2090/4885TSHR 3459/4885POLB 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.